# US 2013/0157989 A1 · 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157989 A1
- Document ID: US20130157989A1
- Status: Published application
- Kind: A1
- Application number: 13/722,957
- Filed: 2012-12-20
- Published: 2013-06-20
- Earliest claimed: 2010-01-28
- Assignees: Theron Pharmaceuticals, Inc.
- Inventors: Jurg R. Pfister; Gwenaella Rescourio; Meenakshi S. Venkatraman; Xiaoming Zhang
- Web page: https://patentgrep.com/patent/US20130157989A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 487/08: Bridged systems
- C07D 487/20: Spiro-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A stereochemically pure compound with a stereochemical purity of at least 80% selected from the group consisting of:
(1S,2R)-2-(R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
(1R,2S)-2-(R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide; and
(1R,2R)-2-(R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide.

### Claim 29 (depends on 28)

The compound of claim 28, wherein the compound is compound (2).

### Claim 30 (depends on 28)

The compound of claim 28, wherein the compound is compound (3).

### Claim 31 (depends on 28)

The compound of claim 28, wherein the compound is (2) or (3) and has a duration of bronchoprotection effect of at least 24 h in guinea pig as defined by the following protocol:
(i) the compound and control (water) are administered to male Dunkin Hartley guinea pigs (250-350 g) via inhalation, by placing the guinea pigs in a dosing chamber and exposing them for 25 min to nebulized drug solution or control using a Pari nebulizer, then returning the animals to their cages;
(ii) twenty-four hours after dosing and thirty minutes prior to the start of pulmonary evaluation, the animals are anesthetized with intramuscular ketamine (55.8 mg/kg), xylazine (3.9 mg/kg) and acepromazine (1 mg/kg), and after anesthesia, the trachea is dissected free and cannulated with a 14G steel tube connected to a pressure transducer (for the measurement of pulmonary inflation pressure) and to a constant volume rodent respirator set to deliver an appropriate tidal volume (2.5 ml) at a rate determined by the animal's weight (100 breath/min), the carotid artery is cannulated with a 5 U/ml heparin/saline-filled PE-50 cannula and connected to a pressure transducer for the measurement of blood pressure and heart rate, and the jugular vein is catheterized with a saline filled polyethylene catheter (PE-10) to be used deliver bolus challenges of the bronchoconstrictor methacholine (MCh);
(iii) intravenous ascending doses of MCh (1 to 300 μg/kg) are administered, after the response to the previous dose returns to baseline; and
(iv) pulmonary inflation pressure and blood pressure are recorded using an appropriate system and/or software.

### Claim 32

A pharmaceutical composition, comprising a stereochemically pure compound with a stereochemical purity of at least 80% selected from the group consisting of:
(1S,2R)-2-(R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
(1R,2S)-2-(R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide; and
(1R,2R)-2-(R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide; and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein the compound is compound (2).

### Claim 34 (depends on 32)

The pharmaceutical composition of claim 32, wherein the compound is compound (3).

### Claim 35 (depends on 32)

The pharmaceutical composition of claim 32, wherein the composition comprises compounds (2) or (3) and has a duration of bronchoprotection effect of at least 24 h in guinea pig as defined by the following protocol:
(i) the compound and control (water) are administered to male Dunkin Hartley guinea pigs (250-350 g) via inhalation, by placing the guinea pigs in a dosing chamber and exposing them for 25 min to nebulized drug solution or control using a Pari nebulizer, then returning the animals to their cages;
(ii) twenty-four hours after dosing and thirty minutes prior to the start of pulmonary evaluation, the animals are anesthetized with intramuscular ketamine (55.8 mg/kg), xylazine (3.9 mg/kg) and acepromazine (1 mg/kg), and after anesthesia, the trachea is dissected free and cannulated with a 14G steel tube connected to a pressure transducer (for the measurement of pulmonary inflation pressure) and to a constant volume rodent respirator set to deliver an appropriate tidal volume (2.5 ml) at a rate determined by the animal's weight (100 breath/min), the carotid artery is cannulated with a 5 U/ml heparin/saline-filled PE-50 cannula and connected to a pressure transducer for the measurement of blood pressure and heart rate, and the jugular vein is catheterized with a saline filled polyethylene catheter (PE-10) to be used deliver bolus challenges of the bronchoconstrictor methacholine (MCh);
(iii) intravenous ascending doses of MCh (1 to 300 μg/kg) are administered, after the response to the previous dose returns to baseline; and
(iv) pulmonary inflation pressure and blood pressure are recorded using an appropriate system and/or software.

### Claim 36 (depends on 32)

The pharmaceutical composition of claim 32, comprising one or more additional therapeutic agents, with the proviso that the one or more additional therapeutic agents are not selected from compounds (1)-(8):
(1S,2S)-2-(R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
(1R,2S)-2-((S)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
(1R,2R)-2-((S)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
(1S,2R)-2-((S)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide; and
(1S,2S)-2-((S)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the one or more additional therapeutic agents are selected from the group consisting of acetylcholine receptor inhibitors, anti-inflammatory agents, bronchodilators, antihistamines, and antitussive agents.

### Claim 38 (depends on 36)

The pharmaceutical composition of claim 36, wherein the one or more additional therapeutic agents are selected from the group consisting of corticosteroids, β2-adrenoreceptor agonists and antitussive agents.

### Claim 39

A method of treating a subject with a disease wherein the disease is a respiratory disease, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a stereochemically pure compound with a stereochemical purity of at least 80% selected from the group consisting of:
(1S,2R)-2-((R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
(1R,2S)-2-((R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
(1R,2R)-2-((R)-2′-cyclopentyl-2′-hydroxy-2′-phenylacetoxy)-7,7-dimethyl-7-azoniabicyclo[2.2.1]heptane bromide;
and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 39)

The method of claim 39, wherein the respiratory disease is selected from the group consisting of respiratory tract disorders, chronic obstructive pulmonary disorder (COPD), chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, rhinorrhea, allergic rhinitis, occupational lung diseases, pneumoconiosis, black lung disease, silicosis, asbestosis, acute lung injury (ALI), and acute respiratory distress syndrome (ARDS).

### Claim 41 (depends on 39)

The method of claim 39, wherein the respiratory disease is chronic obstructive pulmonary disorder (COPD).

### Claim 42 (depends on 39)

The method of claim 39, wherein the respiratory disease is asthma.

### Claim 43 (depends on 39)

The method of claim 39, wherein the respiratory disease is rhinorrhea.

### Claim 44 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition is administered once a day.

### Claim 45 (depends on 39)

The method of claim 39, wherein the compound in the pharmaceutical composition is administered at a dosage of 1 to 500 micrograms per day.

### Claim 46 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition is administered by inhalation.

### Claim 47 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition is administered by using an inhaler selected from the group consisting of a nebulizer, a metered-dose inhaler (MDI), or a dry powder inhaler (DPI).

### Claim 48 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition is administered by intranasal delivery.

### Claim 49 (depends on 39)

The method of claim 39, comprising administering one or more additional therapeutic agents in a single formulation.

### Claim 50 (depends on 49)

The method of claim 49, wherein the one or more additional therapeutic agents are selected from the group consisting of acetylcholine receptor inhibitors, anti-inflammatory agents, bronchodilators, antihistamines, and antitussive agents.
